Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regarding the Article by Rugo et al.
Badaoui S, Rowland A, Sorich MJ, Hopkins AM. Badaoui S, et al. Oncologist. 2021 Jul;26(7):e1285. doi: 10.1002/onco.13781. Epub 2021 Apr 28. Oncologist. 2021. PMID: 33818868 Free PMC article.
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Hopkins AM, et al. Among authors: badaoui s. Br J Cancer. 2022 Jan;126(1):42-47. doi: 10.1038/s41416-021-01606-4. Epub 2021 Oct 28. Br J Cancer. 2022. PMID: 34711947 Free PMC article. Clinical Trial.
A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.
Abuhelwa AY, Badaoui S, Yuen HY, McKinnon RA, Ruanglertboon W, Shankaran K, Tuteja A, Sorich MJ, Hopkins AM. Abuhelwa AY, et al. Among authors: badaoui s. Cancer Chemother Pharmacol. 2022 Apr;89(4):479-485. doi: 10.1007/s00280-022-04411-9. Epub 2022 Feb 28. Cancer Chemother Pharmacol. 2022. PMID: 35226112 Free PMC article. Clinical Trial.
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.
Modi ND, Danell NO, Perry RNA, Abuhelwa AY, Rathod A, Badaoui S, McKinnon RA, Haseloff M, Shahnam A, Swain SM, Welslau M, Sorich MJ, Hopkins AM. Modi ND, et al. Among authors: badaoui s. ESMO Open. 2022 Jun;7(3):100475. doi: 10.1016/j.esmoop.2022.100475. Epub 2022 Apr 28. ESMO Open. 2022. PMID: 35490579 Free PMC article.
29 results